US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

A nationwide surge in flu, COVID-19, RSV and norovirus infections is fueling concerns of a possible virus "quademic." Or is it just winter? The three respiratory viruses plus norovirus ...

Inhalon Biopharma's inhaled RSV antibody treatment will enter human trials marking a potential breakthrough in respiratory ...

Data from the Centers for Disease Control and Prevention showed an increase in three respiratory viruses—COVID-19, flu and RSV—and the gastrointestinal disease norovirus. Emergency department ...

Many health experts have compared HMPV to Respiratory Syncytial Virus (RSV), which can affect all age groups but is more common in children. According to the World Health Organization (WHO), HMPV ...

Cases of influenza, RSV, COVID-19 and norovirus are surging at the same time Cara Lynn Shultz is a writer-reporter at PEOPLE. Her work has previously appeared in Billboard and Reader's Digest.

Nearly 19% of influenza tests are positive, as are about 13% of tests for respiratory syncytial virus (RSV) and 7% of COVID tests, according to CDC data. Those flu and RSV rates are similar to ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased risk for Guillain-Barré Syndrome (GBS) within 42 days of vaccination ...

Cases of flu, COVID and RSV remain high across the U.S., CDC data shows. Respiratory viruses are continuing to spread across the United States, sickening millions of Americans. Overall respiratory ...

Both Lehigh Valley and St. Luke’s University health networks report increased hospitalizations related to influenza and respiratory syncytial virus, two of the most common respiratory infections ...